The FDA approves Menactra vaccine for infants as young as 9 months of age, providing a new option to help protect against meningococcal disease. The vaccine has been shown to elicit a robust immune response and can be administered concurrently with other vaccines.
New data demonstrate Vimpat (lacosamide) C-V's sustained efficacy in reducing seizure frequency and improving responder rates when added to a broad range of antiepileptic drugs. Long-term results show improved seizure control for up to 5 years, with median percent reductions in seizure frequency ranging from 45.5% to 71.8%.
UCB has announced an oral solution formulation of Vimpat (lacosamide) C-V, expanding treatment options for people with epilepsy. The new formulation is available in three forms, including oral solution and IV injection, allowing patients to maintain consistent treatment across various clinical settings.
A new study found that improved treatment of severe epilepsy could significantly reduce the overall cost of the condition. The study analyzed data from 9,163 epilepsy patients and found that non-AED related costs increased disproportionately with disease severity, while AED-related costs remained stable.
New data from the RECOVER study showed that Neupro (Rotigotine Transdermal System) effectively improved both motor and non-motor symptoms of Parkinson's disease, including sleep quality, mood, cognition, and pain. The treatment also translated into significant improvements in quality of life for patients.
New data presented at the American Academy of Neurology annual meeting showed that patients with moderate to severe RLS using rotigotine achieved sustained improvements in symptoms over 5 years. The study confirmed the safety and efficacy of rotigotine, with over a third of patients remaining symptom-free after 5 years.
A Phase III clinical study published online in Epilepsia found that Vimpat (lacosamide) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy. The study showed that patients taking Vimpat had greater reductions in seizure frequency and a higher 50% responder rate compared to placebo.
Researchers found that implantation of blue light-filtering IOLs at cataract surgery increased macular pigment levels, which may offer protection against age-related macular degeneration. The study suggests a strong scientific rationale for the benefits of blue light-filtering in reducing vision loss.
A Phase III clinical study published online in Epilepsia found that Vimpat significantly reduced seizure frequency per 28 days from baseline compared to placebo. The study demonstrated efficacy in patients with uncontrolled partial-onset seizures, with higher rates of seizure reduction and complete seizure freedom among those receiving...
Vimpat demonstrates statistically significant efficacy as early as the first week of treatment, with consistently significant results for both primary endpoints starting at doses of 100 mg/day. The drug shows a significant reduction in seizure frequency versus placebo, with a 39.1% increase in patients experiencing a 50% or greater red...
A Phase III study found that the high-dose influenza vaccine increased immune responses to all three influenza strains compared to the standard vaccine in adults 65 years old and older. The new vaccine also showed increased immune response in those with no measurable protective antibodies before vaccination.
The study found TMC125 effective against highly NNRTI-resistant HIV strains in patients failing treatment. The drug showed no signs of resistance development and was well-tolerated during the trial.
Researchers found that patients taking Bupropion SR lost statistically significant more weight than those in the placebo group during a 24-week initial period. After 48 weeks, patients who received Bupropion SR continued to lose weight, with an average of 8.6% and 7.5% body weight loss.
The Aventis Pasteur statement emphasizes the continued development of its ALVAC vector as a preventive AIDS vaccine. The company remains committed to multiple trials using ALVAC-HIV (vCP1452) and supports research into its therapeutic potential, with ongoing phase I/II studies underway.
The new guidelines recommend increasing use of single antiepileptic drugs before combination therapies, while also addressing special needs for women and older adults. Estimated 2.3 million Americans have epilepsy, with half being female.
In a phase IIa trial, TMC125 demonstrated a rapid and strong antiviral effect, reducing HIV viral loads by up to 99.9%. The study showed that 8 out of 12 patients had their viral loads reduced to less than 400 copies/ml without any rebound or drug resistance.
A double-blind, placebo-controlled study found that patients with diabetic neuropathy experienced significant pain reduction with Lamictal treatment. Almost half of the patients achieved a 50% reduction in pain, and most were able to reduce their need for additional pain medication.
A retrospective study of 681 HIV-positive patients found that Virco's VirtualPhenotype? and Antivirogram? resistance tests accurately predicted treatment outcomes. Patients receiving three or four active drugs experienced significant reductions in viral load and increases in CD4 cell counts.
A landmark survey shows that patients with major depression often feel their illness isn't under complete control and experience few quality-of-life improvements. The study highlights a significant communication gap between primary care physicians and patients, leading to inadequate treatment and side effect management.
A study has confirmed that VirtualPhenotype can accurately predict HIV therapy response using genetic resistance information, outperforming expert interpretation. This standardized approach offers a reliable alternative for optimal treatment decision-making.
Researchers found that smokers who continued using the smoking cessation aid Zyban gained an average of 9.02 pounds less than those on placebo over 45 weeks. Women in this group lost significantly more weight, with an average loss of 13.86 pounds at 52 weeks.
A 12-week study found that 49% of patients treated with Zyban had not used tobacco for the previous four weeks, compared to 26% in the placebo group. The three-month figures showed a slight increase in quit rates, but further research is needed.
A study analyzing a maintenance use trial found that people who quit smoking using placebo cited overwhelming cravings as the most frequent reason for returning to smoking. In contrast, those treated with Zyban (bupropion HCl) Sustained-Release 150 mg Tablets, cited presence of other smokers and stress as top reasons.
The study found that 27.2% of HIV patients were resistant to all three classes of drugs, while 29.1% had resistance to two classes and 21.9% were resistant to one. This underscores the importance of resistance testing for treatment decision-making in HIV clinical practice.
Researchers have developed a new technique for detecting atypical cells in breast ducts, which could identify pre-cancerous abnormalities years before mammographically detectable lesions develop. A device that retrieves ductal cells has shown promising results in clinical trials, identifying abnormal cells in 15% of the population.
Researchers presented data from an ongoing Phase I clinical trial showing that CCI-779, a derivative of rapamycin, is well-tolerated and may have antitumor activity. Twelve patients received CCI-779, with three experiencing tumor regression after other treatments failed.
Depression affects not only individuals but also their intimate relationships. This guide provides valuable coping strategies to maintain connections during depression. It answers questions from patients and partners, offering expertise from seven authorities on managing depression-related intimacy problems.
The 90th Annual Meeting of American Association for Cancer Research will showcase groundbreaking research in translational cancer research, including anti-angiogenesis agents, cancer vaccines, gene therapy, and molecular targeted therapy. The meeting will feature over 5,000 abstracts and 200 invited presentations from leading experts.